Pharmidex attending the Global Business Accelerator visit to Switzerland
March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days


The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.


Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies. 


During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days. 


We look forward to meeting you there.

May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.
April 27, 2026
The success of your research starts with the right model, at the right time. At Pharmidex, we deliver tailored GA breeding solutions combining expert colony management, flexible study design, and rigorous quality control. Backed by AAALAC-accredited facilities and a strong commitment to the 3Rs, we ensure reliable, study-ready models with full traceability. From breeding strategy and genotyping to scalable capacity and flexible timelines, we act as an extension of your team, helping accelerate your research with confidence. 🔬 The right models. When you need them. 🚀 Flexible. Reliable. Research-focused. Let’s build your next breeding strategy.
More Posts